Daily Stock Analysis, BTX, BioTime Inc, priceseries

BioTime Inc. Daily Stock Analysis
Stock Information
Open
9.95
Close
10.04
High
10.24
Low
9.63
Previous Close
9.73
Daily Price Gain
0.31
YTD High
80.67
YTD High Date
May 3, 2021
YTD Low
3.59
YTD Low Date
Apr 1, 2021
YTD Price Change
5.40
YTD Gain
116.38%
52 Week High
80.67
52 Week High Date
May 3, 2021
52 Week Low
3.10
52 Week Low Date
Sep 24, 2020
52 Week Price Change
6.56
52 Week Gain
188.51%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 12. 2018
9.22
Jan 30. 2018
10.32
11 Trading Days
11.89%
Link
LONG
Jan 7. 2019
4.28
Jan 23. 2019
5.42
11 Trading Days
26.62%
Link
LONG
Sep 9. 2019
5.24
Sep 10. 2019
5.57
1 Trading Days
6.30%
Link
LONG
Sep 23. 2019
4.90
Oct 3. 2019
5.72
8 Trading Days
16.78%
Link
LONG
Jun 15. 2020
2.50
Jun 22. 2020
4.63
5 Trading Days
85.05%
Link
LONG
Oct 13. 2020
3.58
Oct 27. 2020
4.26
10 Trading Days
19.00%
Link
LONG
Jan 19. 2021
5.10
Feb 5. 2021
9.01
13 Trading Days
76.64%
Link
LONG
Feb 9. 2021
9.14
Feb 19. 2021
9.84
7 Trading Days
7.60%
Link
LONG
Apr 9. 2021
6.43
Apr 13. 2021
6.96
2 Trading Days
8.32%
Link
LONG
Apr 14. 2021
6.07
May 6. 2021
41.41
16 Trading Days
582.22%
Link
LONG
Jun 18. 2021
15.95
Jun 30. 2021
18.07
8 Trading Days
13.27%
Link
LONG
Aug 24. 2021
10.41
Sep 14. 2021
11.97
14 Trading Days
14.94%
Link
Company Information
Stock Symbol
BTX
Exchange
NYSE MKT
Company URL
http://www.biotimeinc.com
Company Phone
5105213390
CEO
Michael D. West
Headquarters
California
Business Address
1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA, CA 94501
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000876343
About

BioTime, Inc. engages in biotechnology business. It focuses on research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.

Description

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. Its product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. The company also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products. Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. Additionally, the company develops and markets Hextend, a blood plasma volume expander used for the treatment of hypovolemia. BioTime, Inc. was founded in 1990 and is based in Alameda, California.